A response to high-dose estrogen for tamoxifen, aromatase inhibitor and trastuzumab refractory HER2+ and ER+ advanced breast cancer
نویسندگان
چکیده
A response to high-dose estrogen for tamoxifen, aromatase inhibitor and trastuzumab refractory HER2+ and ER+ advanced breast cancer.
منابع مشابه
Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer.
BACKGROUND To review the efficacy of chemotherapy and human epidermal growth factor receptor 2 (HER2)-targeted therapy when used in addition to hormonal therapy for the optimal management of estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-positive (HER2+) breast cancer. DESIGN Literature published from January 2003 to March 2008 was reviewed to assess the use of chem...
متن کاملافقهای پزشکی فردی در درمان سرطان پستان : مقاله مروری
Breast cancer that is caused by the accumulation of genetic and epigenetic alterations, is one of the main causes of death resulted from cancer. Various therapeutic approaches have been introduced for this cancer and the traditional diagnosis and treatment is based on the prognosis estimation using cancer anatomic features (TNM system) and clinical results, but studies show different responses ...
متن کاملCrosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.
Data suggest that breast cancer growth is regulated by coordinated actions of the estrogen receptor (ER) and various growth factor receptor signaling pathways. In tumors with active growth factor receptor signaling (e.g., HER2 amplification), tamoxifen may lose its estrogen antagonist activity and may acquire more agonist-like activity, resulting in tumor growth stimulation. Because treatments ...
متن کاملTargeted Therapy for Breast Cancer Prevention
With a better understanding of the etiology of breast cancer, molecularly targeted drugs have been developed and are being testing for the treatment and prevention of breast cancer. Targeted drugs that inhibit the estrogen receptor (ER) or estrogen-activated pathways include the selective ER modulators (tamoxifen, raloxifene, and lasofoxifene) and aromatase inhibitors (AIs) (anastrozole, letroz...
متن کاملCan molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer?
PURPOSE Resistance to tamoxifen is linked to overexpression of HER2, and aromatase inhibitors show particular benefit in progesterone receptor (PR)-negative patients. We previously reported reduced survival in patients overexpressing HER1, HER2, and HER3. We now show that both HER1-3 and PR status predicts for early relapse in estrogen receptor (ER)-positive tamoxifen-treated breast cancer pati...
متن کامل